- Title
- SAFETY AND ACTIVITY OF TEMSIROLIMUS AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA PREVIOUSLY TREATED WITH TYROSINE KINASE INHIBITORS: A PHASE 2 CONSORTIUM STUDY
- Creators
- Jaime R Merchan - University of Miami Sylvester Comprehensive Cancer Center, Miami, FLRui Qin - Mayo Clinic, Rochester, MNHenry Pitot - Mayo Clinic, Rochester, MNJoel Picus - Washington University School of Medicine, St Louis, MOGlenn Liu - University of Wisconsin Carbone Cancer Center, Madison WITom Fitch - Mayo Clinic Arizona, Scottsdale, AZWilliam J Maples - Mayo Clinic Jacksonville, Jacksonville, FLPatrick J Flynn - Metro Minnesota CCOP, St Louis Park, MNBriant F Fruth - Mayo Clinic, Rochester, MNCharles Erlichman - Mayo Clinic, Rochester, MN
- Publication Details
- Cancer chemotherapy and pharmacology, Vol.75(3), pp.485-493
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 25556030
- PMCID
- PMC4348698
- Record Identifier
- 991031561457302976
Journal article
SAFETY AND ACTIVITY OF TEMSIROLIMUS AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA PREVIOUSLY TREATED WITH TYROSINE KINASE INHIBITORS: A PHASE 2 CONSORTIUM STUDY
Cancer chemotherapy and pharmacology, Vol.75(3), pp.485-493
2015-03
PMCID: PMC4348698
PMID: 25556030
Metrics
12 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.233 Pelvic & Renal Disorders
- 1.233.501 Renal Cell Carcinoma
- Web Of Science research areas
- Oncology
- Pharmacology & Pharmacy
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites